Generation of Clinically Applicable CAR-NKT Cells Research Background Chimeric Antigen Receptor (CAR) T cell therapy has been approved by the Food and Drug Administration (FDA) for the treatment of B-cell malignancies and multiple myeloma. However, the use of autologous CAR-T cell products presents challenges such as high costs, long manufacturing ...

Role of Syndecan Binding Protein (SDCBP) in Regulating Tumor Microenvironment, Tumor Progression, and Anti-PD1 Efficacy in Colorectal Cancer Background In recent years, immunotherapy has brought revolutionary advancements in cancer treatment. However, for colorectal cancer (CRC), anti-programmed cell death 1 (APD1) therapy shows relatively limited ...